Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years an
4 days ago
- #acute lymphoblastic leukemia
- #hematopoietic cell transplantation
- #GVHD prophylaxis
- Study compares ATG and alemtuzumab for GVHD prophylaxis in older ALL patients undergoing reduced-intensity HCT.
- Patients aged ≥40 with ALL in first complete remission were pair-matched by age and subtype.
- Two-year outcomes (leukemia-free survival, overall survival, relapse, non-relapse mortality) were similar between groups.
- GVHD and infections were main causes of death in both groups.
- Both ATG and alemtuzumab are deemed safe for RIC HCT in this patient population.